the Committee on Appropriations of the Senate; and
(D) the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies of the Committee on Appropriations of the House of Representatives.

(b) Final report.—
(1) In general.—Not later than 180 days after the date of enactment of this Act, the Secretary of Agriculture shall submit to the Committees and Subcommittees described in subsection (a)(2) a final report that—
(A) describes the economic impacts associated with the potential introduction of foot and mouth disease, bovine spongiform encephalopathy, and related diseases into the United States;
(B) discusses the potential risks to public and animal health from foot and mouth disease, bovine spongiform encephalopathy, and related diseases; and
(C) provides recommendations to protect the health of animal herds and citizens of the United States from those risks including, if necessary, recommendations for additional legislation, appropriations, or product bans.

(2) Contents.—The report shall contain—
(A) an assessment of the risks to the public presented by the potential introduction of foot and mouth disease, bovine spongiform encephalopathy, and related diseases in domestic and imported livestock, livestock products, wildlife, and blood products;
(B) recommendations to reduce and manage the risks of foot and mouth disease, bovine spongiform encephalopathy, and related diseases;
(C) any plans of the Secretary to identify, prevent, and control foot and mouth disease, bovine spongiform encephalopathy, and related diseases in domestic and imported livestock, livestock products, wildlife, and blood products;
(D) a description of the incidence and prevalence of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in other countries;
(E) a description and analysis of the effectiveness of the measures taken to prevent, assess, and control the risks of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States, including controls of ports of entry and other conveyances;
(F) any plans of Federal agencies (including the Centers for Disease Control and Prevention) to prevent and control the spread of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States and other countries;
(G) a description of the measures taken to prevent and control the spread of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States and related activities undertaken by public and private health officials;
(H) a description of any measures (including any planning or managerial initiatives such as interagency, intergovernmental, international, and public-private sector partnerships) that any Federal agency plans to initiate or continue to assess, prevent, and control the spread of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States and other countries;
(I) plans by Federal agencies (including the Centers for Disease Control and Prevention)
(ii) to assess the effectiveness of efforts to prevent and control the spread of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States;
(J) plans by Federal agencies (including the Agricultural Research Service, the Cooperative State Research, Education, and Extension Service, and the National Institutes of Health) to carry out, in partnership with the private sector—
(a) research programs into the causes and mechanism of transmission of foot and mouth disease and bovine spongiform encephalopathy;
(b) diagnostic tools and preventive and therapeutic agents for foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases;
(K) plans for providing appropriate compensation for affected animals in the event of the introduction of foot and mouth disease, bovine spongiform encephalopathy, or related diseases into the United States; and
(L) recommendations to Congress for legislation that will improve efforts to assess, prevent, or control the transmission of foot and mouth disease, bovine spongiform encephalopathy, variant Creutzfeldt-Jacob disease, and related diseases in the United States and in other countries.

(c) Consultation.—
(1) Preliminary report.—In preparing the preliminary report under subsection (a), the Secretary shall consult with—
(A) the Secretary of State;
(B) the Secretary of Commerce;
(C) the Secretary of Health and Human Services;
(D) representatives of other appropriate Federal agencies;
(E) the United States Trade Representative;
(F) the Secretary of Defense;
(G) the Director of the Federal Emergency Management Agency; and
(H) representatives of other appropriate Federal agencies.

(2) Final report.—In preparing the final report under subsection (b), the Secretary shall consult with—
(A) the individuals listed in paragraph (1);
(B) private and nonprofit sector experts in infectious disease, research, prevention, and control;
(C) international, State, and local governmental and non-governmental animal health officials;
(D) private, nonprofit, and public sector livestock experts;
(E) representatives of blood collection and distribution entities; and
(F) representatives of consumer and patient organizations and other interested members of the public.

EXECUTIVE SESSION